Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ARS Pharmaceuticals (SPRY) Non-Current Assets (2021 - 2025)

Historic Non-Current Assets for ARS Pharmaceuticals (SPRY) over the last 5 years, with Q3 2025 value amounting to $33.9 million.

  • ARS Pharmaceuticals' Non-Current Assets rose 28515.66% to $33.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $106.3 million, marking a year-over-year increase of 72756.15%. This contributed to the annual value of $16.9 million for FY2024, which is 105307.8% up from last year.
  • According to the latest figures from Q3 2025, ARS Pharmaceuticals' Non-Current Assets is $33.9 million, which was up 28515.66% from $32.0 million recorded in Q2 2025.
  • In the past 5 years, ARS Pharmaceuticals' Non-Current Assets registered a high of $51.1 million during Q1 2022, and its lowest value of $265000.0 during Q3 2022.
  • For the 5-year period, ARS Pharmaceuticals' Non-Current Assets averaged around $14.3 million, with its median value being $3.9 million (2021).
  • Per our database at Business Quant, ARS Pharmaceuticals' Non-Current Assets crashed by 9943.86% in 2022 and then skyrocketed by 250879.48% in 2025.
  • ARS Pharmaceuticals' Non-Current Assets (Quarter) stood at $716000.0 in 2021, then skyrocketed by 421.65% to $3.7 million in 2022, then plummeted by 60.86% to $1.5 million in 2023, then soared by 1053.08% to $16.9 million in 2024, then skyrocketed by 101.33% to $33.9 million in 2025.
  • Its last three reported values are $33.9 million in Q3 2025, $32.0 million for Q2 2025, and $23.5 million during Q1 2025.